Eton Pharmaceuticals, Inc.
ETON Healthcare Drug Manufacturers Specialty & Generic
Eton Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.0 million, up 104.9% from fiscal 2024. In the quarter to June 2026, revenue grew 98.6%, EPS grew 520.0%, free cash flow fell 8.78% and total debt fell 7.54%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow ETON
Eton Pharmaceuticals, Inc. (ETON) EV/Sales
As of 16 October 2026, Eton Pharmaceuticals, Inc. (ETON) trades at a EV/Sales of 13.2×. Over the past ten years it has ranged from 0.0× (June 2020) to 5,059× (February 2021); the current reading is higher than 86% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.7× | (38.37%) |
| FY2024 | 9.3× | 178.73% |
| FY2023 | 3.3× | 13.28% |
| FY2022 | 3.0× | (35.76%) |
| FY2021 | 4.6× | (99.89%) |
| FY2020 | 4,014× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 9.5× | 20.48% |
| Mar 2026 | 7.9× | 36.96% |
| Dec 2025 | 5.7× | (30.02%) |
| Sep 2025 | 8.2× | 23.17% |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PAHC Phibro Animal Health Corporation compare | 1.5× |
| ANIP ANI Pharmaceuticals, Inc. compare | 1.8× |
| AMPH Amphastar Pharmaceuticals, Inc. compare | 2.0× |
| CRON Cronos Group Inc. compare | 2.3× |
| PCRX Pacira BioSciences, Inc. compare | 2.3× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 2.6× |
| HROW Harrow, Inc. compare | 4.5× |
| XERS Xeris Biopharma Holdings, Inc. compare | 5.7× |
| ETON Eton Pharmaceuticals, Inc. | 13.2× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)